dexamethasone,Elotuzumab,lenalidomide
Abbvie,BMS
['mmsm', 'krd ']
one additional point noted by dr. knop: mrd-negativity with elokrd post-induction was 52.6% vs 37.5% with krd #mmsm #asco23 
Asst Professor at University of Chicago, specializing in (vanquishing) plasma cell disorders. I tweet about: Myeloma & MRD. https://t.co/mPeWg1QRrW